ReviewMarine drugs2023
Immunopotentiating Activity of Fucoidans and Relevance to Cancer Immunotherapy.
Review in Marine drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Marine Food Polysaccharides: Representative Structural Features, Immunomodulatory Effects, and Food Applications.Marine drugs · 2026Review
- Targeting Leukopoiesis: Pharmacological and Biotechnological Strategies for the Treatment of Leukopenia.Biomedicines · 2026Review
- Navigating the challenges in fucoidan industrialization: factors affecting biological activity and strategies for application of functional material.Food science and biotechnology · 2026Review
- Sulfated Polysaccharides in Wound Healing: From Bioactive Materials Design to Regenerative Therapeutics.International journal of nanomedicine · 2026Review
- Overview of Primary and Secondary Metabolites ofMarine drugs · 2025Review
- Recombinant protein CP01850 adjuvanted with Iridea cordata or Sacorpletis skottibergii lipid extracts protected mice against infection by Corynebacterium pseudotuberculosis.Biotechnology letters · 2025Article
- Imine Crosslinked, Injectable, and Self-Healing Fucoidan Hydrogel with Immunomodulatory Properties.Advanced healthcare materials · 2025Article
- The pathogenesis of diabetic kidney disease and the therapeutic potential of bioactive substances.Frontiers in pharmacology · 2025Review
- Natural Food Components as Biocompatible Carriers: A Novel Approach to Glioblastoma Drug Delivery.Foods (Basel, Switzerland) · 2024Review
- Natural products as promising modulators of breast cancer immunotherapy.Frontiers in immunology · 2024Review
- The functional role of L-fucose on dendritic cell function and polarization.Frontiers in immunology · 2024Article
- From nature to clinic: Quercetin's role in breast cancer immunomodulation.Frontiers in immunology · 2024Review
- Chemical Composition, Antioxidant, and Antitumor Activity of Fucoidan from the Brown AlgaMolecules (Basel, Switzerland) · 2023Article
- Marine Natural Products as Anticancer Agents 2.0.Marine drugs · 2023Article
- Physicochemical Characterization and Antitumor Activity of Fucoidan and Its Degraded Products fromMolecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fucoidans, discovered in 1913, are fucose-rich sulfated polysaccharides extracted mainly from brown seaweed. These versatile and nontoxic marine-origin heteropolysaccharides have a wide range of favorable biological activities, including antitumor, immunomodulatory, antiviral, antithrombotic, anticoagulant, antithrombotic, antioxidant, and lipid-lowering activities. In the early 1980s, fucoidans were first recognized for their role in supporting the immune response and later, in the 1990s, their effects on immune potentiation began to emerge. In recent years, the understanding of the immunomodulatory effects of fucoidan has expanded significantly. The ability of fucoidan(s) to activate CTL-mediated cytotoxicity against cancer cells, strong antitumor property, and robust safety profile make fucoidans desirable for effective cancer immunotherapy. This review focusses on current progress and understanding of the immunopotentiation activity of various fucoidans, emphasizing their relevance to cancer immunotherapy. Here, we will discuss the action of fucoidans in different immune cells and review how fucoidans can be used as adjuvants in conjunction with immunotherapeutic products to improve cancer treatment and clinical outcome. Some key rationales for the possible combination of fucoidans with immunotherapy will be discussed. An update is provided on human clinical studies and available registered cancer clinical trials using fucoidans while highlighting future prospects and challenges.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.